Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body. All to treat cancers, blood issues, blindness, cystic fibrosis, and muscular dystrophy. All of which is creating substantial opportunities for some of the leading gene editing stocks. What’s more exciting is companies like Profluent Bio “leveraged artificial intelligence to design an open-source gene editor called OpenCRISPR-1, demonstrating the technology can be used to crea ...